Wire · operational-macro
FDA announces HBV drug approval, GLP-1 receptor agonist warning
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 November 2026 · Fusion42 review
The FDA approved bepirovirsen injection as the first antisense oligonucleotide treatment for certain chronic hepatitis B patients without cirrhosis and added boxed warnings for serious liver reactions. It also granted accelerated approval to dostarlimab for specific rectal cancer cases and mandated a new safety warning for GLP-1 receptor agonists regarding potential optic nerve damage.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face tighter regulatory scrutiny on liver safety in HBV drugs and new entry points in rectal cancer treatment approvals. This shift opens a compliance gate while raising risks in GLP-1 therapies that you must manage.
◆ Coverage
1 source · 20 Nov 2026
◆ Related on Wire
◆ Topics